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ABSTRACT 
 
In recent years, it has become almost axiomatic that biomedical research and clinical 
practice should be ‘innovative’—that is, that they should be always evolving and directed 
towards the production, translation and implementation of new technologies and practices. 
While this drive towards innovation in biomedicine might be beneficial, it also raises serious 
moral, legal, economic and socio-political questions that require further scrutiny. In this 
article, we argue that biomedical innovation needs to be accompanied by a dedicated 
‘bioethics of innovation’ that attends systematically to the goals, process and outcomes of 
biomedical innovation as objects of critical inquiry. Using the example of personalized or 
precision medicine, we then suggest a preliminary framework for a bioethics of innovation, 
based on the research policy initiative of ‘Responsible Innovation’. We invite and encourage 
critiques of this framework, and hope that this will provoke a challenging and enriching new 
bioethical discourse.  
 
 
 
The drive to innovate in medicine and the need for a supporting ‘bioethics of innovation’ 
 
Anyone working in medicine will be aware of the rapidly changing nature of biomedical 
research and clinical practice, and the drive to ‘innovate’,[1-4]—that is to produce new 
knowledge and technologies—and ‘translate’[5-8] or ‘implement’[9-11] these into policy and 
practice as quickly as possible. Governments worldwide have called for greater investments 
in biomedical innovation and translation,[12-18] and attempts have been made to change 
legislation so that innovation can be take place more freely in science and medicine.[19] 
Researchers, policymakers and practitioners have made similar pleas, as typified by 
statements such as this one in Academic Medicine:   
 
Health care environments must foster innovation, not just allowing it but actively 
encouraging it to happen anywhere and at every level in health care and medicine—
from the laboratory, to the operating room, bedside, and clinics.[3 p1424] 
 
Not surprisingly, given the current drive to innovate in medicine, many popular definitions of 
biomedical innovation assume that such innovation is always desirable. The World Health 
Organisation, for example, states that: ‘[i]nnovative technologies refer to novel medical 
(device) solutions that address health problems and improve quality of life.’[14] We argue, 
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in contrast, that biomedical innovation per se is neither good nor bad and that the concept 
itself deserves critical attention. To facilitate this attention, we believe that there is a need 
for a bioethics of innovation that provides a moral and socio-political framework for thinking 
about the values, goals, processes and outcomes of biomedical innovation (as distinct from 
those of specific emerging technologies) as an object of scrutiny. 
 
Current bioethical approaches to innovation 
 
When it comes to examining novel or ‘innovative’ technologies, bioethicists have long been 
interested in evaluating the moral implications of specific ‘emerging technologies’. As a 
result, sophisticated frameworks have been developed for thinking about the potential (and 
often unpredictable) positive and negative implications of specific technologies, such as 
nanotechnology, stem cell therapies, or bio-enhancement [20]  
 
Insofar as bioethicists have focused on the process of innovation, the emphasis has tended 
to be on how to respect and safeguard the human research participants who take risks in 
order to facilitate innovation, and whether and how to encourage the use of particular 
‘tools’ of innovation, such as animal models, embryonic stem cells or biobanks. Bioethicists 
have also developed sophisticated frameworks for thinking about how to ensure that 
patients have equitable access to the products of innovation, without placing too great a 
burden on health system resources.[21]   
 
These preoccupations of bioethicists who are interested in emerging technologies can be 
demonstrated by examining the bioethical discourse surrounding ‘personalised’ or 
‘precision’ medicine’—a key component of the ever-more popular ‘translational medicine’ 
paradigm.[12, 13, 22-25] In keeping with the typical bioethical concerns described above, 
bioethicists with an interest in new ‘personalised’ therapies have generally focused their 
attention on the morality of specific laboratory technologies—such as cloning—used in the 
pursuit of personalised medicine; research ethics questions, such as how to protect those 
participating in increasingly complex clinical trials and those who donate tissue to the 
biobanks that are used to identify biomarkers; and resource allocation questions, such as 
how to ensure equity and efficiency in the funding and distribution of personalised 
medicines and companion diagnostics.[26-29] 
 
These are important moral and socio-political issues, but to focus solely on these types of 
issues potentially obscures a broader set of questions focused on health-related innovation 
itself—i.e. on the practices, politics and ethics of the development of novel health 
technologies, and of making changes to existing, more or less evidence-based health-related 
practices. Here, bioethics appears to have less to say. 
 
This lacuna has long been recognised by social scientists, who have worried about the 
institutionalisation of bioethics as a set of governance tools that downplays both the politics 
of innovation and the uncertainties inherent in knowledge and technology production. In 
response, they have suggested that there is a need to shift attention ‘upstream’, away from 
just the risks and impacts of innovation and towards its processes, as well as a need to make 
innovation more democratically accountable.[30, 31] 
 
This is not to say that bioethicists are completely uninterested in innovation as an object of 
inquiry.  Debates about whether legislation should be passed that makes it easier for 
clinicians to try new treatment strategies;[32] whether, when and how surgeons should try 
out new operative techniques;[33] and how to conceptualise and manage the prescribing of 
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unregistered medicines,[34] all point to concerns within the bioethics community about 
innovative practice outside the context of formal biomedical research.  But each of these 
issues tends to be dealt with in isolation, rather than by drawing on a framework that 
attends systematically to the goals, process and outcomes of any kind of biomedical 
innovation.  In the remainder of this article, we will outline a potential framework for a 
‘bioethics of innovation’ that might be able to fill this gap.  
 
Developing a bioethics of innovation based on Responsible Innovation 
 
Fortunately those with an interest in developing a bioethics of innovation would not need to 
start from scratch, and could draw upon a set of frameworks that have already been 
developed for innovation in general: those of ‘Responsible Innovation’ or ‘Responsible 
Research and Innovation’.[35] In recent years, Responsible Innovation has garnered much 
attention and traction as a policy and scholarly agenda. For example, it is now used as a 
multi-institutional policy tool in Europe, and the Journal of Responsible Innovation was 
launched in 2014.[36]  
 
The Responsible Innovation agenda has emerged as a result of recognition of both the many 
unquestioned assumptions underpinning innovation, and an apparent loss of public trust in 
innovation. It has also been stimulated by the concern that those governing science 
(including bioethicists) have tended to focus too much on protecting individual consumers 
from the potential harms associated with specific products of innovation. Scholars in this 
field have therefore argued that there is a need to ‘move from the governance of risk to the 
governance of innovation itself.’[35 p1570]   
 
Responsible Innovation aims to be forward-looking—‘taking care of the future through 
collective stewardship of science and innovation in the present.’[35 p1570] It also aims to 
embed societal deliberation into the innovation process. As Stahl has noted, Responsible 
Innovation comprises a number of ‘actors’, ‘activities’ and ‘norms’, and proposes a view of 
Responsible Innovation as: 
 
‘a higher-level responsibility or meta-responsibility that aims to shape, maintain, 
develop, coordinate and align existing and novel research and innovation-related 
processes, actors and responsibilities with a view to ensuring desirable and 
acceptable research outcomes.’[37 p708] 
 
One foundational conceptualization of Responsible Innovation, that has been put forward by 
Stilgoe and colleagues focuses on a set of four principles or dimensions, namely: 
anticipation, reflexivity, inclusion, and responsiveness. Anticipation calls for a consideration 
of desirable futures of the technology; reflexivity calls for scientists and institutions to 
engage in moral reflection about innovation; inclusion calls for new voices to be brought 
into the governance of science and innovation; and responsiveness refers to the need for 
attention to the political (e.g. regulatory) and commercial (e.g. intellectual property) forces 
that may hold power over innovation, as well as the need for courses of innovation to be 
adjusted according to emerging findings from the three previous domains[35] In addition to 
considering specific technologies, such as nanomedicine,[38] synthetic biology,[39] and 
theranostics,[40], discourses of Responsible Innovation have been used widely to examine 
the socio-political ethical, moral, legal, and economic issues arising in technology innovation 
more broadly.[41, 42] 
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Despite this widespread use of Responsible (Research and) Innovation in research policy and 
scholarship, it is important to note that Responsible Innovation has often not been 
deliberately and explicitly attentive to the context of health in biomedical research.  This is 
potentially a problem because there are some features of health innovations that make 
them different from other kinds of innovations. Health products and service innovations are 
different from consumer product innovations, both in the contexts in which there are 
produced, and the contexts in which they are consumed—and this uniqueness of health is 
often obscured in discussions of innovation in general.[43-45].  To this end, we suggest that 
a framework of Responsible Innovation that is attentive to health and biomedicine should 
form the foundation of a bioethics of innovation. 
 
It should also be noted that the paradigm of Responsible Innovation has itself been criticised 
for being somewhat limited in its focus on certain elements of ‘responsibility’ and not others 
(e.g. on responsibility to certain publics but not others), and on the potentially atheoretical 
and acritical notion its puts forward of ‘responsibility” in innovation.[41] However, we 
emphasise that Responsible Innovation should only be the broad organising framework for a 
complete bioethics of innovation.  In developing a comprehensive bioethics of innovation—
i.e. in ‘fleshing out’ the Responsible Innovation framework in the context of health and 
biomedical innovation—it will also be crucial to draw upon insights from other biomedical 
disciplines focused on the study and critique of biomedicine.  
 
Other sources of guidance for a bioethics of innovation 
 
Insights to inform a bioethics of innovation could, for example, be derived from the social 
and political sciences, including science and technology studies (STS), social epistemology, 
sociology and anthropology of science and medicine, and organizational studies, where the 
organisational and political dimensions of scientific practice and technological development 
are explored.[46-49] While these disciplines tend to be analytic rather than prescriptive, 
they do provide a rich understanding of the social norms, values and power relations that 
underpin biomedical innovation, and that need to be taken into account in any application 
of a bioethics of innovation.  In particular, as mentioned above, the field of STS has long 
established the need for reflexivity and democratic participation in technological innovation, 
and for focusing not only on downstream risk, but also on the cultural and political 
dimensions of technology.[30] Knowledge about norms, values, power relations, and 
political factors derived from these social science disciplines could be particularly helpful in 
achieving the principles of reflexivity (which requires reflection on embedded norms and 
values), genuine inclusiveness (which requires identification and management of power 
imbalances), and responsiveness by illuminating the effects on innovation of governance and 
regulatory regimes, and social institutions. 
 
Health economics, with its focus on cost-benefit analyses, the allocation of resources, and 
economic health technology assessment, could also provide useful insights for a bioethics of 
innovation.[50] It is noteworthy that a view is emerging that those assessing health 
technologies should focus not only on clinical safety, effectiveness and cost-effectiveness, 
but also on aligning technology development with population values, and defining and 
rewarding genuine (value-adding) innovation.[51] Insights from health economics and 
technology assessment could be particularly helpful when it comes to the anticipation 
dimension of responsible innovation, which entails identifying unmet needs and determining 
whether they can, or cannot, be met by a particular emergent technology, as well as 
responsiveness by grounding the field in health-related economic insights.[48, 52, 53]  
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Those interested in developing a framework for a bioethics of innovation could also draw on 
insights from applied disciplines such as ‘implementation science,’[9, 10, 54] ‘translation 
science,’[6-8, 55-57] and ‘research and innovation policy.’[58, 59] It is important to bear in 
mind, however, that these disciplines tend to focus on questions of how to foster and speed 
up innovation through, for example, removing organisational barriers, rather than on 
whether innovation should be promoted, and what harms or competing goals need to be 
balanced against the benefits of innovation.  Nonetheless, an understanding of the dynamics 
of biomedical implementation and translation could assist in ensuring that new technologies 
are developed with the appropriate degree of responsiveness to barriers to implementation, 
and to changing clinical, economic and social circumstances. 
 
Finally, while bioethics in its current form is lacking in its approach to the totality of 
innovation, bioethics is a dynamic field, and some emerging sub-fields within bioethics could 
shed light on some of the moral complexities of a bioethics of innovation. Public health 
ethics, global health ethics, and health policy ethics[60-63] all focus on broad systems, 
populations and processes, and might therefore, provide useful conceptualisations for those 
with an interest in developing a bioethics of innovation.  These domains of bioethics are 
promising in their macro-level approaches to bioethics, and though the focus on innovation 
is currently limited within them, insights could be systematically developed on how the 
conceptualization of public interests, global agendas, and policy processes affect biomedical 
innovation.  
 
Other branches of applied ethics, such as academic ethics[64], business ethics[65] and 
publication ethics[66] could also shine light on the moral dilemmas and obligations of 
particular stakeholders in biomedical innovation processes, particularly by focussing a 
bioethics of innovation on how the commitments of academic institutions, such as 
publication and research, affect innovation agendas; or how business arrangements and 
obligations impact upon innovation cycles .  Furthermore, the normative theories upon 
which bioethics is based, such as virtue ethics, principlism, consequentialism, and 
examinations of justice, may provide useful frameworks for thinking about the process of 
innovation.  
 
Scope of a bioethics of innovation 
 
In order to be sufficiently comprehensive, it would be important for a bioethics of 
innovation to attend systematically to all dimensions of biomedical innovation, from the 
conceptualisation of a new health technology through to its development, testing, 
manufacture, registration, funding, marketing, and implementation in practice.  
 
Returning to our case of personalized medicine, and using Stilgoe et al’s framework for 
Responsible Innovation as an organising framework, a exemplar set of critical questions 
would include: 
 Anticipation: What forces (political, economic, or social) have determined that 
targeted therapies and companion diagnostic should be developed and promoted, 
and what is driving this commitment? Is there a defined (and ideally currently 
under-served) patient population who would benefit from the development of 
personalised medicine (e.g. individuals with genetic mutations that render existing 
treatments ineffective)?   How will the unanticipated consequences of targeted 
therapies be dealt with, beyond simple risk mitigation? 
 Reflexivity: Have ethical, social and political concerns been taken into account in the 
development of personalised medicine? For example, given that personalised 
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medicines and companion diagnostics are often so expensive, has thought been 
given to whether the technology will be affordable for the target patient population 
or purchaser? Will genetic testing for relevant biomarkers lead to genetic 
discrimination for individuals who carry that trait?  
 Inclusiveness: (How) have stakeholders (patients, citizens, regulators, 
payers/insurers and lay and professional caregivers) been involved in the 
development, regulation, funding and translation of personalised medicines? Has 
this been done in a manner that accounts for differential power structures (e.g. the 
difference in power between regulators or the pharmaceutical industry and patients 
with rare forms of cancer)? 
Responsiveness:  Has the process of developing personalised medicines been 
attentive to political, social and economic barriers to implementation (e.g. slow 
regulatory and clinical uptake of targeted therapies)? How will contemporary 
biomedical publication practices, and the forces of (both academic and commercial) 
intellectual property protection affect the development of, and access to targeted 
therapies and their companion genetic diagnostic tools, and how can knowledge and 
benefit sharing be encouraged within these systems? When and how should 
targeted therapies be introduced into practice (including for uses that might run 
contrary to regulatory, funding or clinical guidelines)? Who should be responsible for 
monitoring them? How will the development or commercialization and 
implementation of personalised medicine be reconsidered in the context of new 
information about targeted therapies, and in the context of other emergent 
technologies? 
 
A comprehensive bioethics of innovation would also need to acknowledge that biomedical 
innovation, and the challenges it aims to address, exist on a global scale, and that innovation 
is shaped by the secularization, individualization, pluralisation and fragmentation of Western 
societies. As Stahl observes, all of these forces lead simultaneously to ‘the increased 
importance of research and innovation’ and the ‘decreasing ability to steer it using 
conventional science and innovation governance measures.’[37 p709]  
 
A bioethics of innovation would therefore need to attend to the moral and socio-political 
dimensions of ‘bigger picture’ influences on health and biomedicine, including the effects of 
globalisation of biomedical research, where biomedical innovation is concurrently expected 
to cross national borders and also provide national health and economic benefits; changing 
relationships between academic, political and commercial stakeholders, where, for example, 
political forces increasingly encourage and foster academic research commercialization; 
changing global economic regimes, favouring industrialization and economization in health 
research; changing global and regional regulatory and legal environments, with an increased 
focus on knowledge ownership and trade-related intellectual property protection; increasing 
imperatives towards consumer engagement in health-related innovation; changing 
biomedical scientific paradigms (e.g. towards targeted therapies, genetic manipulations, and 
more broadly differing understandings of ‘evidence’ in the production of scientific 
knowledge); and new information technologies and systems.[35, 60, 67-69] 
 
Conclusion 
 
We have argued that, while the drive towards innovation in biomedicine might be beneficial, 
it is also a domain that requires scrutiny and moral questioning, and needs to be 
accompanied by a systematic and sophisticated ‘bioethics of innovation.’ We have argued 
that this bioethics of innovation could draw upon frameworks of Responsible Innovation, as 
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well as a number of other relevant disciplines. While we have focused in this article on 
biomedical innovation, we see no reason that these ideas could not be applied to health-
related innovation more generally, including public health and health services innovation. 
We hope that this will provide a starting point for a challenging and enriching new bioethical 
discourse.  
 
 
References 
 
1. Saatchi M. How can an Act of Parliament cure cancer? J R Soc Med 2013;106:169-72. 
2. Mirza Z, Krattiger A, Taubman A, et al. Policy coherence for improved medical innovation 
and access. Bull World Health Organ 2013;91:315-15. 
3. Dzau VJ, Yoediono Z, ElLaissi WF, et al. Fostering innovation in medicine and health care: 
what must academic health centers do? Acad Med 2013;88:1424-29. 
4. Abbasi K. Innovation, the new panacea. J R Soc Med 2013;106:163-63. 
5. US Preventive Services Taskforce. US Preventive Services Taskforce.  [cited 2015 Sep 10]. 
Available from: http://www.uspreventiveservicestaskforce.org 
6. Ergorul C, Levin LA. Solving the lost in translation problem: improving the effectiveness of 
translational research. Curr Opin Pharmacol 2013;13:108-14. 
7. Levin LA, Danesh-Meyer HV. Lost in translation: bumps in the road between bench and 
bedside. JAMA 2010;303:1533-34. 
8. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011;3. 
9. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services 
research findings into practice: a consolidated framework for advancing 
implementation science. Implement Sci 2009;4. 
10. Solomon MZ. The ethical urgency of advancing implementation science. Am J Bioeth 
2010;10:31-32. 
11. Glasgow RE, Vinson C, Chambers D, et al. National Institutes of Health approaches to 
dissemination and implementation science: current and future directions. Am J 
Public Health 2012;102:1274-81. 
12. Wells RD. A new President, a new Congress and the path to personalized medicine. Pers 
Med 2009;6:235-39. 
13. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-
04. 
14. World Health Organization. Call for innovative technologies that address global health 
concerns.  Available at:  http://www.who.int/medical_devices/call/en/ [Accessed 29 
July 2015] 
15. Erlichman J. Innovation At NIH: it’s in their DNA. 2012. Available at:  
http://breakinggov.com/2012/05/07/innovation-at-national-institutes-of-health-its-
in-their-dna/ [Accessed 17 Jan 2014] 
16. Canadian Institutes of Health Research. CIHR’s commercialization and innovation 
strategy. 2005. Available at: http://www.cihr-irsc.gc.ca/e/30162.html [Accessed 17 
Jan 2014] 
17. NPR. Transcript: Obama's State of the Union address. 2011. Available at:  
http://www.npr.org/2011/01/26/133224933/transcript-obamas-state-of-union-
address [Accessed 15 Dec 2013] 
18. National Health Service. NHS Chief Executive Innovation Review: call for evidence and 
ideas. 2011. Available at:  https://http://www.gov.uk/government/publications/nhs-
chief-executive-innovation-review [Accessed 15 Dec 2013] 
19. Dyer C. Government gives backing to Saatchi bill. BMJ 2014;349. 
20. Brey PAE. Anticipatory ethics for emerging technologies. Nanoethics 2012;6:1-13. 
 8 
21. Millum J, Emanuel E, eds. Global Justice and Bioethics. New York: Oxford University Press 
2012. 
22. Fu Q, Schoenhoff FS, Savage WJ, et al. Multiplex assays for biomarker research and 
clinical application: translational science coming of age. Proteomics Clin Appl 
2010;4:271-84. 
23. Waldman SA, Terzic A. Widening the path to personalized medicine. Clin Transl Sci 
2011;4:392-94. 
24. Kondro W. Paving the path to personalized medicine. Can Med Assoc J 2012;184:E221-
E22. 
25. Zerhouni EA. Translational research: moving discovery to practice. Clin Pharmacol Ther 
2007;81:126-28. 
26. Langanke M, Brothers KB, Erdmann P, et al. Comparing different scientific approaches to 
personalized medicine: research ethics and privacy protection. Pers Med 
2011;8:437-44. 
27. Gefenas E, Cekanauskaite A, Tuzaite E, et al. Does the "new philosophy" in predictive, 
preventive and personalised medicine require new ethics? EPMA J 2011;2:141-7. 
28. Meslin EM, Cho MK. Research ethics in the era of personalized medicine: updating 
science's contract with society. Public Health Genomics 2010;13:378-84. 
29. Petersen A. The ethics of expectations: biobanks and the promise of personalised 
medicine. Monash Bioeth Rev 2009;28:1-12. 
30. Wynne B. Risk and environment as legitimatory discourses of technology: reflexivity 
inside out? Current sociology 2002;50:459-77. 
31. Wilsdon J, Willis R. See-through science: why public engagement needs to move 
upstream: Demos 2004. 
32. Richards B, Porter G, Lipworth W, et al. The Medical Innovation Bill: still more harm than 
good. Clin Ethics 2015;Published online 25/2/2015. 
33. Rogers WA, Lotz M, Hutchison K, et al. Identifying surgical innovation: a qualitative study 
of surgeons' views. Ann Surg 2014;259:273-78. 
34. Walker MJ, Rogers WA, Entwistle V. Ethical justifications for access to unapproved 
medical interventions: an argument for (Limited) patient obligations. Am J Bioeth 
2014;14:3-15. 
35. Stilgoe R, Macnaghten P. Developing a framework for responsible innovation. Res Policy 
2013;42:1568-80. 
36. Guston D, Fisher E, Grunwald A, et al. Responsible innovation: motivations for a new 
journal. Journal of Responsible Innovation 2014;1:1-8. 
37. Stahl BC. Responsible research and innovation: the role of privacy in an emerging 
framework. Science and Public Policy 2013;40:708-16. 
38. Oftedal G. The role of philosophy of science in Responsible Research and Innovation 
(RRI): the case of nanomedicine. Life Sci Soc Policy 2014;10:5-5. 
39. Douglas CMW, Stemerding D. Governing synthetic biology for global health through 
responsible research and innovation. Syst Synth Biol 2013;7:139-50. 
40. Fisher E, Boenink M, van der Burg S, et al. Responsible healthcare innovation: 
anticipatory governance of nanodiagnostics for theranostics medicine. Expert Rev 
Mol Diagn 2012;12:857-70. 
41. Guston D. Responsible innovation: who could be against that? Journal of Responsible 
Innovation 2015;2:1-4. 
42. Owen R, Bessant J, Heintz M, eds. Responsible Innovation: Managing the Responsible 
Emergence of Science and Innovation in Society. West Sussex: Wiley 2013. 
43. French M, Miller FA. Leveraging the "living laboratory": on the emergence of the 
Entrepreneurial Hospital. Soc Sci Med 2012;75:717-24. 
 9 
44. Miller FA, Sanders CB, Lehoux P. Imagining value, imagining users: academic technology 
transfer for health innovation. Soc Sci Med 2009;68:1481-88. 
45. Lehoux P, Williams-Jones B, Miller F, et al. What leads to better health care innovation? 
Arguments for an integrated policy-oriented research agenda. J Health Serv Res 
Policy 2008;13:251-54. 
46. Sismondo S. An Introduction to Science and Technology Studies. 2nd ed. West Sussex UK: 
Wiley-Blackwell 2011. 
47. Littlejohns P, Weale A, Chalkidou K, et al. Social values and health policy: a new 
international research programme. J Health Organ Manag 2012;26:285-92. 
48. Duthie K, Bond K. Improving ethics analysis in health technology assessment. Int J 
Technol Assess Health Care 2011;27:64-70. 
49. Abelson J, Giacomini M, Lehoux P, et al. Bringing 'the public' into health technology 
assessment and coverage policy decisions: from principles to practice. Health Policy 
2007;82:37-50. 
50. Cookson R, Claxton K, eds. The Humble Economist: Tony Culyer on Health, Health Care 
and Social Decision Making. York: University of York and London: Office of Health 
Economics 2012. 
51. Ijzerman MJ, Steuten L. Early assessment of medical technologies to inform product 
development and market access. Appl Health Econ Health Policy 2011;9:331-47. 
52. Gauvin F-P, Abelson J, Giacomini M, et al. "It all depends": conceptualizing public 
involvement in the context of health technology assessment agencies. Soc Sci Med 
2010;70:1518-26. 
53. Hofmann BM. Why ethics should be part of health technology assessment. Int J Technol 
Assess Health Care 2008;24:423-29. 
54. Lobb R, Colditz GA. Implementation science and Its application to population health. 
Annu Rev Public Health 2013;34:235-51. 
55. Honey K. Translating medical science around the world. J Clin Investig 2007;117:2737-37. 
56. Reis SE, Berglund L, Bernard GR, et al. Reengineering the National Clinical and 
Translational Research Enterprise: the Strategic Plan of the National Clinical and 
Translational Science Awards Consortium. Acad Med 2010;85:463-69. 
57. Zerhouni EA. Translational and clinical science - time for a new vision. New Engl J Med 
2005;353:1621-23. 
58. Brownson R, Colditz G, Proctor E, eds. Dissemination and Implementation Research in 
Health: Translating Science to Practice. New York: Oxford University Press 2012. 
59. Jacobs D. The Cultural Side of Innovation: Adding Values. London: Routledge 2013. 
60. Lipworth WL, Kerridge IH, Day RO. Formulating an ethics agenda for drug development, 
regulation, and utilization. Ther Innov Regul Sci 2013;47:46-49. 
61. Dawson A, ed. Public Health Ethics: Key Concepts and Issues in Policy and Practice. 
Cambridge: Cambridge University Press 2011. 
62. Benatar S, Brock G, eds. Global Health and Global Health Ethics. Cambridge: Cambridge 
University Press 2011. 
63. Danis M, Clancy C, Churchill L, eds. Ethical Dimensions of Health Policy. New York: Oxford 
University Press 2002. 
64. Cahn S. Morality, Responsibility, and the University: Studies in Academic Ethics. 
Philadelphia: Temple University Press 2010. 
65. Woiceshyn J. A model for ethical decision making in business: reasoning, intuition, and 
rational moral principles. J Bus Ethics 2011;104:311-23. 
66. Graf C, Wager E, Bowman A, et al. Best practice guidelines on publication ethics: a 
publisher’s perspective. Int J Clin Pract 2007;61:1-26. 
67. Thakur R, Hsu SHY, Fontenot G. Innovation in healthcare: issues and future trends. J Bus 
Research 2012;65:562-69. 
 10 
68. Kaitin K. Deconstructing the drug development process: the new face of innovation. Clin 
Pharmacol Ther 2010;87:356-61. 
69. Thiers F, Sinskey A, Berndt E. Trends in the globalization of clinical trials. Nat Rev Drug 
Discov 2008;7:13-14. 
 
